ORIC Pharmaceuticals, Inc.

DB:4TZ Stock Report

Market Cap: €664.8m

ORIC Pharmaceuticals Future Growth

Future criteria checks 0/6

ORIC Pharmaceuticals's earnings are forecast to decline at 6.9% per annum while its annual revenue is expected to grow at 69.6% per year. EPS is expected to grow by 4% per annum. Return on equity is forecast to be -49.6% in 3 years.

Key information

-6.9%

Earnings growth rate

4.0%

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth rate69.6%
Future return on equity-49.6%
Analyst coverage

Good

Last updated20 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:4TZ - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202611-185-150-1649
12/31/2025N/A-161-123-12711
12/31/2024N/A-127-97-8911
9/30/2024N/A-120-110-109N/A
6/30/2024N/A-111-100-100N/A
3/31/2024N/A-102-96-95N/A
12/31/2023N/A-101-87-86N/A
9/30/2023N/A-93-78-77N/A
6/30/2023N/A-93-78-76N/A
3/31/2023N/A-90-75-73N/A
12/31/2022N/A-89-77-75N/A
9/30/2022N/A-91-78-76N/A
6/30/2022N/A-85-71-69N/A
3/31/2022N/A-85-69-67N/A
12/31/2021N/A-79-60-60N/A
9/30/2021N/A-84-62-61N/A
6/30/2021N/A-91-59-59N/A
3/31/2021N/A-81-53-52N/A
12/31/2020N/A-74-46-45N/A
9/30/2020N/A-54-35-35N/A
6/30/2020N/A-35-31-30N/A
3/31/2020N/A-30-27-26N/A
12/31/2019N/A-27-24-24N/A
12/31/2018N/A-21-21-21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4TZ is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4TZ is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4TZ is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4TZ is forecast to have no revenue next year.

High Growth Revenue: 4TZ is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4TZ is forecast to be unprofitable in 3 years.


Discover growth companies